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Abstract Adhalin is deficient in two forms of human muscular 
dystrophy, one due to mutations in the adhalin gene and one 
linked to an unidentified gene on chromosome 13. Because 
adhalin is deficient in skeletal and cardiac muscles of BIO 14.6 
hamsters, which experience both myopathy and cardiomyopathy, 
cDNA encoding adhalin from BIO 14.6 hamster skeletal muscle 
was cloned and sequenced. Adhalin mRNA was expressed at 
normal levels in BIO 14.6 hamster cardiac muscle, and no muta- 
tion in adhalin coding sequence was found, indicating that the 
inherited myopathy and cardiomyopathy of the BIO 14.6 hamster 
are most likely not due to mutations in the adhalin gene. 
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I. Introduction 
Duchenne muscular dystrophy results from mutations in the 
gene encoding dystrophin, a muscle membrane cytoskeletal 
protein [1]. In normal muscle, dystrophin is complexed with 
several dystrophin-associated proteins (~-dystroglycan, syntro- 
phin, adhalin, fl-dystroglycan, 43DAG or A3b, 35DAG, and 
25DAP) to form the dystrophin-glycoprotein complex. The 
N-terminus of dystrophin binds to filamentous actin and c~- 
dystroglycan binds to laminin, indicating that one function of 
the dystrophin-glycoprotein complex is to link the actin cy- 
toskeleton to the extracellular matrix (reviewed in [2]). Due to 
the loss of dystrophin, all dystrophin-associated proteins are 
greatly reduced in abundance in skeletal muscle from Duch- 
enne muscular dystrophy patients [3,4], mdx mice [5], and dys- 
trophic golden retrievers [6]. 
An identical or antigenically similar complex of proteins has 
been identified in cardiac muscle [7,8]. Cardiac dystrophin- 
glycoprotein complex colocalizes with laminin to the cardiac 
sarcolemma and T-tubule system [8], in contrast with skeletal 
muscle in which the dystrophin-glycoprotein complex is absent 
from T-tubules [9]. The dystrophin-associated proteins are 
preserved in mdx cardiac muscle, presumably by forming 
a complex with utrophin, an autosomal homologue of dys- 
trophin, or Dp71, a C-terminal transcript from the dystrophin 
gene [7]. 
Cardiomyopathies develop in patients uffering from Duch- 
enne muscular dystrophy and in patients having some other 
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forms of muscular dystrophy [10,11]. Additionally, the inbred 
B IO 14.6 hamster develops both an autosomal recessive muscu- 
lar dystrophy and cardiomyopathy [12-14]. The cardiomyopa- 
thic hamster (CMH) is a widely studied animal model of hy- 
pertrophic ardiomyopathies n which cardiac ellular necrosis 
accompanied by a loss of sarcolemmal integrity begins 3(L40 
days after birth in 100% of animals homozygous for the disease 
[12]. Primary cell damage ceases by 80 days of age, but calcium 
deposits and excess connective tissue remain [12]. Progressive 
hypertrophy followed by dilatation leads to congestive heart 
failure and death at less than half the normal life span [14]. 
Several biochemical bnormalities in the CMH heart have been 
described, but the genetic defect in the BIO 14.6 strain has not 
been identified. 
Dystrophin is present at nearly normal evels in the cardio- 
myopathic hamster, but the link between dystrophin and 
WGA-binding lycoproteins is totally disrupted in CMH skele- 
tal [15] and cardiac [16] muscle. All dystrophin-associated pro- 
teins are decreased in abundance in CMH cardiac muscle as 
determined by immunofluorescence [15,16]. However, in CMH 
skeletal muscle dystrophin and all dystrophin-associated pro- 
teins are present at normal levels except adhalin, the 50-kDa 
dystrophin-associated glycoprotein, which is totally deficient 
[15-17], and 35DAG, which is reduced in abundance [15,17]. 
Interestingly, this is the same pattern of staining observed in 
patients with severe childhood autosomal recessive muscular 
dystrophy [3]. 
The cDNA encoding adhalin has been cloned from rabbit 
[18] and human [19] skeletal muscle. Adhalin mRNA [18,19] 
and protein [20] is expressed almost exclusively in skeletal and 
cardiac muscles. The human adhalin gene is located on chromo- 
some 17q, and various missense, nonsense, and frameshift mu- 
tations in the adhalin gene have been identified in multiple 
families with autosomal recessive muscular dystrophy ([19]; and 
F. Piccolo, S.L.R., K.P.C., J.-C. Kaplan, et al., unpublished 
data). Another form of autosomal recessive muscular dystro- 
phy is caused by mutations in an unidentified gene on chromo- 
some 13q [21], and at least some patients linked to markers on 
chromosome 13q have a deficiency of adhalin in skeletal muscle 
[22]. Thus, at least two genetic defects can lead to adhalin 
deficiency. 
In this report we investigated whether mutations in the 
adhalin gene might cause the myopathy and cardiomyopathy 
of BIO 14.6 cardiomyopathic hamsters. However, adhalin 
mRNA was expressed at normal levels in cardiomyopathic 
hamsters and no mutations in the coding sequence of adhalin 
were identified by sequence analysis. Thus, the inherited mus- 
cular dystrophy and cardiomyopathy of the BIO 14.6 hamster 
are most likely not due to mutations in the adhalin gene. 
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3. Results 
2. Materials and methods 
Male FIB control and BIO 14.6 cardiomyopathic golden Syrian 
hamsters were obtained from Bio Breeders, Fitchburg, MA. 8-Week- 
old male CHF146 and CHF147 cardiomyopathic hamsters and male 
and female golden Syrian and albino control hamsters were obtained 
from Canadian Hybrid Farm, Centreville, N.S., Canada. Animals were 
housed and sacrificed in accordance with institutional guidelines. The 
affinity-purified sheep antibody against adhalin [5] and monoclonal 
antibody IIH6 against dystroglycan [23] were previously described. 
Skeletal muscle (7 pm) cryosections were immunostained asdescribed 
[15]. Cardiac membranes were prepared as described [5] from age- 
matched hamsters and fractionated on 3 12% gradient SDS-poly- 
acrylamide gels, transferred to nitrocellulose, and stained with antibod- 
ies as previously described [9]. 
Total skeletal or cardiac muscle RNA was isolated from FIB or BIO 
14.6 hamsters using RNAzol (Tel-Test), and poly(A) ÷ RNA was puri- 
fied using the mRNA Separator kit (Clonetech). For cDNA library 
construction, FIB or BIO 14.6 hamster skeletal muscle cDNA was 
synthesized with NotI/EcoRl adapters using a kit from Pharmacia, 
cDNA was ligated into 2ZAPII (Stratagene), and bacteriophage DNA 
was packaged using Gigapack Gold II (Stratagene). Libraries were 
screened by hybridization according to Stratagene's protocol using 
rabbit adhalin cDNA to screen the FIB library and subsequently the 
FIB hamster adhalin clone to screen the BIO 14.6 library. Polymerase 
chain reaction was performed using Taq polymerase from Boehringher- 
Mannheim and a Perkin-Elmer thermal cycler. Sequencing was per- 
formed using an Applied Biosystems automated sequencer. Northern 
blot analysis was performed as described [18]. 
2 wk 
To more clearly determine whether adhalin was a reasonable 
candidate for causing the myopathy and cardiomyopathy of the 
BIO 14.6 hamster, the expression of adhalin was examined at 
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Fig. 2. Adhalin is deficient in two independent s rains of cardiomyopa- 
thic hamsters derived from the BIO 14.6 line. Identical immunoblots 
of cardiac membranes from Golden Syrian (GS), cardiomyopathic line 
CHF146, albino (Alb), and cardiomyopathic l ne CHF147 hamsters 
were stained with an affinity-purified sheep antibody against adhalin 
or monoclonal antibody IIH6 against ~-dystroglycan. Molecular 
weight standards (Mr x 10 -3) are indicated. 
Control CMH 
I 
1 
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Fig. 1. Deficiency of adhalin in BIO 14.6 hamsters at early ages. Trans- 
verse skeletal muscle cryosections from 2-, 6-, or 10-week-old normal 
(Control) or BIO 14.6 cardiomyopathic (CMH) hamsters were labeled 
by indirect immunofluorescence with an affinity-purified sheep anti- 
body against adhalin. 
various time points in young hamsters. As shown in Fig. l, the 
loss of adhalin was observed prior to and throughout the time 
course of myocytolysis in the cardiomyopathic hamster. Addi- 
tionally, adhalin was undetectable in a 3-day-old cardiomyopa- 
thic hamster bred from B10 14.6 hamsters in our laboratory 
(data not shown). Thus, loss of adhalin precedes the onset of 
myopathy and cardiomyopathy, suggesting that the deficiency 
of this protein may play a role in the pathogenesis of these 
disease states. 
Because our previous work [15] describing the deficiency of 
adhalin in cardiomyopathic hamsters used BIO 14.6 hamsters 
from Bio Breeders, we felt the need to confirm that adhalin was 
deficient in other colonies of cardiomyopathic hamsters. The 
BIO 14.6 strain of golden Syrian hamsters was derived from the 
original myopathic BIO 1.50 line [24]. Subsequently, a UM-  
X7.1 line was established at the University of Montreal by 
breeding BIO 14.6 hamsters with a strain of healthy animals 
[14]. Colonies of cardiomyopathic hamsters from a common 
origin are maintained at various laboratories around the world. 
Because of this, adhalin deficiency should not necessarily be 
maintained if it is not directly related to the disease process. 
We analyzed two strains of cardiomyopathic hamsters from 
Canadian Hybrid Farm in Nova Scotia: the CHF146 line de- 
rived from BIO 14.6 and the CHF l47  line derived from UM- 
X7.1, along with two healthy hamster lines. Adhalin was defi- 
cient in cardiac membranes from both cardiomyopathic lines 
but was easily detectable in normal hamsters (Fig. 2). a-Dystro- 
glycan was greatly reduced in abundance in cardiac membranes 
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RABBIT  
HUMAN 
HAMSTER 
MAAAALLWLPLLVGCLAGPGGTEAQQTTLYPLVGRVFVHTLEPASFLHLP  50 
MAET-LFWTPLLVVLLAGLGDTEAQQTTLHPLVGRVFVHTLDHETFLSLP  49 
MAAT-LTWILLFVGLLAGLRDTKAQQTTLYPLVGRVFVHPLEHATFLRLP  49  
** * * * .*  ***  * ******  *********  *. .** ** 
RABBIT  
HUMAN 
HAMSTER 
EHAA-PAT IPVTYHAHLQGHPDLPRWLRYTQRSPHHPGFLYGAATPEDRG 99 
EHVAVPPAVHITYHAHLQGHPDLPRWLRYTQRSPHHPGFLYGSATPEDRG 99 
EHIAVPPTVRLTYQAHLQGHPDLPRWLRYTQRSPYSPGFLYGTPTPEDRG 99 
** . * . .** ********************  ******  ******  
RABBIT  
HUMAN 
HAMSTER 
RQVIEVTAYNRDSFDTAGQSLVLL IRDPEGSPLPYQTEFLVRSHDVEEVL  149 
LQVIEVTAYNRDSFDTTRQRLVLE IGDPEGPLLPYQAEFLVRSHDAEEVL  149  
RQVIEVTAYNRDSFDTTRQRLLLL IEDPEGPRLPYQAEFLVRSHDVEEVL  149  
***************  * * .*  * ****  ****  ********  ****  
RABBIT  
HUMAN 
HAMSTER 
RABBIT  
HUMAN 
HAMSTER 
PPTPASHFLTALAGLWEPGELKLLNITSALDRGGRVPLP IGGQKEGVYIK  199  
PSTPASRFLSALGGLWEPGELQL~SALDRGGRVPLP IEGRKEGVYIK  199  
PSTPANRFLTALGGLWELGELQLLNITSALDRGGRVPLP IEGRKEGVYIK  199 
* ***  . * * . ** . ****  ***  *** . **************  * *******  
VGSASPFSTCLKMVASPDSHARCARGQPPLLSCYDTLAPHFRVDWCNVSL  249  
VGSASPFSTCLKMVASPDSHARCAQGQPPLLSCYDTLAPHFRVDWCNVTL  249  
VGSATPFSTCLKMVASPDSYARCAQGQPPLLSCYDSLAPHFRVDWCNVSL  249  
**** . **************  ****  *************************  
RABBIT  
HUMAN 
HAMSTER 
VDTSVPEPVDEVPTPGDGILEHDPFFCPPTEATARDFLADALVTLLVPLL  299  
VDKSVPEPADEVPTPGDGILEHDPFFCPPTEAPDRDFLVDALVTLLVPLL  299  
VDKSVPEPLDEVPTPGDGILEHDPFFCPPTEATGRDFLADALVTLLVPLL  299  
** *****  ***********************  ****  ***********  
RABBIT  
HUMAN 
HAMSTER 
VALLLALLLAY IMCCRREGRLKRDLATSDIQMVHHCTIHENTEELRQMAA 349 
VALLLTLLLAYVMCCRREGRLKRDLATSDIQMVHHCTIHGNTEELRQMAA 349 
VALLLTLLLAY IMCCRREGQLKRDMATSDIQMVHHCTIHGNTEELRQMAA 349 
*****  ***** . *******  ****  **************  **********  
RABBIT  SREVPRPLSTLPMFNVRTGERMPPRVDSAQVPL ILDQH 387 
HUMAN SREVPRPLS  TLPMFNVHTGERLPPRVDSAQVPL  I LDQH 387 
HAMSTER RREVPRPLSTLPMFNVRTGERLPPRVDSAQVPL  I LDQH 387 
*************** .  * ***  ****************  
Fig. 3. Alignment of rabbit, human, and hamster adhalin amino acid sequences. Amino acids that are identical among all three species are indicated 
by an asterisk; conservative substitutions are indicated by a dot. Two extracellular potential N-linked glycosylation sites, five extracellular cysteines, 
and an intracellular consensus site for phosphorylation by Ca:*/calmodulin-dependent protein kinase are conserved. The nucleotide sequence r ported 
in this paper has been submitted to GenBank/EMBL Data Bank with Accession No. U21677. 
isolated from both strains of cardiomyopathic hamsters, as it 
is in BIO 14.6 hamsters [15]. However, ~-dystroglycan is pres- 
ent at normal levels in cardiomyopathic hamster skeletal muscle 
[15], suggesting that the dystroglycan gene is unlikely to be 
affected. These results demonstrate that three separately main- 
tained strains of cardiomyopathic hamsters from a single ge- 
netic origin share a deficiency of adhalin and ~-dystroglycan i
cardiac muscle. 
Normal hamster adhalin cDNA was isolated by constructing 
and screening a hamster skeletal muscle cDNA library using 
rabbit adhalin cDNA [48] as a probe. The longest characterized 
clone contained 1332 bp, including 4 bp of 5' untranslated 
sequence and 167 bp of 3' untranslated sequence (including a 
polyadenylation signal) based on homology to rabbit and 
human adhalin. 
The deduced amino acid sequence of hamster adhalin is 
shown in Fig. 3. Hamster, human, and rabbit adhalin are 80% 
identical at the amino acid level, and homology is 86% when 
including conservative substitutions. Two consensus ites for 
N-linked glycosylation, a potential phosphorylation site for 
Ca2+/calmodulin-dependent pro ein kinase, and five extracellu- 
lar cysteines are conserved in all three species. Four of these 
cysteines are closely spaced in a manner bearing some homol- 
ogy to extracellular domains of entactin and nerve growth fac- 
tor receptor, suggesting that adhalin may bind to an extracellu- 
lar matrix component or other cell-surface molecule. 
Adhalin mRNA was present at normal levels and at appar- 
ently normal size in cardiomyopathic hamster cardiac muscle 
(Fig. 4). This suggests that either the adhalin gene is unaffected 
in BIO 14.6 hamsters or that mutations in the adhalin gene do 
not affect transcription, splicing, or stability of adhalin mRNA 
and must not involve large deletions or insertions within tran- 
scribed regions. Thus, screening for adhalin mutations must 
involve searching for point mutations or small deletions or 
insertions within the translated mRNA, and thus cDNA, se- 
quence. 
To search for mutations in adhalin cDNA, a BIO 14.6 ham- 
ster skeletal muscle cDNA library was constructed and 
screened using normal (FIB) hamster adhalin cDNA as a 
probe. One 1301-bp clone was obtained having its 5' end at the 
sixth translated nucleotide and having 145 bp of 3' untranslated 
sequence. Additionally, BIO 14.6 hamster adhalin cDNA was 
amplified by PCR from reverse-transcribed BIO 14.6 skeletal 
muscle poly(A) ÷ RNA using oligonucleotides corresponding 
to nucleotides -43 to -24 of human adhalin 5' untranslated 
sequence [19] and hamster adhalin nucleotides 1300 1322. 
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Fig. 4. Adhalin mRNA is present at normal levels in BIO 14.6 hamster 
cardiac muscle. A Northern blot containing 5 ,ug per lane of F1B 
(Control) or BIO 14.6 (CMH) hamster cardiac total RNA was hybrid- 
ized with a hamster adhalin cDNA probe. The autoradiograph was 
exposed for 4 days. RNA size standards (kilobases) are indicated. 
Sequencing of BIO 14.6 hamster adhalin cDNA obtained by 
both methods revealed that cardiomyopathic hamster adhalin 
cDNA was identical to that from normal hamsters. 
4. Discussion 
Adhalin is deficient in BIO 14.6 cardiomyopathic hamsters 
prior to and after the onset of myocytolysis. Additionally, 
adhalin deficiency has been confirmed in three separately main- 
tained strains of cardiomyopathic hamsters, indicating that it 
would be a reasonable candidate for being the primary cause 
of muscular dystrophy and cardiomyopathy in this strain of 
hamsters. Consistent with this hypothesis the recent finding 
that mutations in the human adhalin gene can cause muscular 
dystrophy [19]. However, no mutations were found in the cod- 
ing region of BIO 14.6 hamster adhalin cDNA, and Northern 
blot analysis indicated that adhalin mRNA is transcribed nor- 
mally and is stable in cardiomyopathic amster heart. Because 
the complete 5' untranslated region has not been isolated, it 
remains trictly possible that mutations upstream of known 
sequence could adversely affect the translation of adhalin. 
However, it appears very unlikely that mutations inthe adhalin 
gene are responsible for the myopathy and cardiomyopathy of 
BIO 14.6 hamsters. 
Interestingly, adhalin deficiency in human muscular dystro- 
phies has been observed not only in patients with mutations in
the adhalin gene [19], but also in patients linked to an uniden- 
tified gene on chromosome 13q [22]. It is possible that the 
defective gene in the cardiomyopathic hamster is homologous 
to the muscular dystrophy gene on human chromosome 13q. 
Although cardiomyopathy is not common in individuals with 
chromosome 13q-linked muscular dystrophy, a few individuals 
with adhalin deficiency and cardiomyopathy ave been identi- 
fied (Y. Sunada nd K.P.C., unpublished data). Regardless, the 
affected gene in cardiomyopathic hamsters must affect the ex- 
pression of adhalin in both skeletal and cardiac muscles [15-17]. 
Such a gene may encode a chaperone protein, an adhalin- 
binding protein (either intracellular, on the cell surface, or in 
the extracellular matrix), or another component of the dystro- 
phin-glycoprotein complex. The identification of the defective 
gene in the BIO 14.6 hamster will likely increase our knowledge 
of the function of adhalin and the entire dystrophin-glycopro- 
tein complex. 
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